{"id":"W1966385883","doi":"10.1007/s10549-014-3221-2","title":"Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study","year":2014,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hôpital du Saint-Sacrement; Ottawa Regional Cancer Foundation; Montreal General Hospital; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal","funders":"NSABP Foundation; GlaxoSmithKline","keywords":"Pazopanib; Medicine; Cyclophosphamide; Oncology; Breast cancer; Paclitaxel; Doxorubicin; Internal medicine; Neoadjuvant therapy; Chemotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004233204,0.0004621738,0.0007506667,0.0001869428,0.0007292218,0.00009751117,0.00007710624,0.00008743512,0.0001665312],"category_scores_gemma":[0.00002041692,0.0003377354,0.0001097947,0.0002551632,0.0003058903,0.0002069799,0.00009104652,0.0002122155,0.000003557399],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007837396,"about_ca_system_score_gemma":0.0005274719,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01181624,"about_ca_topic_score_gemma":0.003038577,"domain_scores_codex":[0.9972771,0.0001999084,0.0003676276,0.0009186029,0.0004675624,0.0007691809],"domain_scores_gemma":[0.9983404,0.0003825084,0.0001186285,0.0002532693,0.0003176449,0.0005875946],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.0187907,0.004952782,0.04166448,0.00007475819,0.001421351,0.00007333678,0.002333469,0.000003830967,0.003876387,0.0001165073,0.0001752297,0.9265172],"study_design_scores_gemma":[0.3151426,0.1328191,0.5107216,0.001187711,0.001649003,0.0006059997,0.005436554,0.001048041,0.008361682,0.001380658,0.02040894,0.001238036],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9777007,0.00957532,0.00003202394,0.006642158,0.00024189,0.005169582,0.0004711999,0.00005321425,0.0001138895],"genre_scores_gemma":[0.9803448,0.01359924,0.00006583873,0.0002045358,0.0003522366,0.004468222,0.00006437751,0.00005487577,0.0008459052],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9252791,"threshold_uncertainty_score":0.9999075,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04808848182568354,"score_gpt":0.4395269584767557,"score_spread":0.3914384766510721,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}